Navigation Links
Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Date:7/23/2009

nnounced in due course.

The Company has sufficient cash at hand to fund operations into August, however the Company will need to raise additional capital to fund its clinical trials and other operating activities, and repay indebtedness in due course. Shareholders should be aware that if the Company's capital raising efforts are unsuccessful, this will have a material adverse effect on the Company's financial position and operations.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is in a large Phase II clinical trial in GBM, with 13 clinical sites across the U.S. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and for Phase I trials in five other cancers. The Company has started, and is currently enrolling patients in, a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information about clinical sites and Company information please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future securities registrations or other filings with the U.S. Securities and Exchange Commission ("SEC"), future treatment of patients with GBM using DCVax(R)-Brain, and other future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such a
'/>"/>

SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
2. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
3. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
4. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
5. Oncothyreon to present at Invest Northwest 2009
6. Sirius Genomics to Present at Invest Northwest Conference
7. Northwest Biotherapeutics Secures $700,000 Equity Financing
8. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
9. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
10. Northwest Secures US$1.65 Million Debt Financing
11. Northwest Secures US$1.0 Million Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industryā€¯ is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... August 18, 2014 Global HIV Infection ... report announced by Reportstack. The rate of HIV infection and ... a declining note at a positive rate across the globe. ... 2.3 million in 2005 to 1.5 in 2013, with the ... for such drastic changes in the infection rates has been ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Will Help Drive Company,s Commercialization of,Eligen(R) Technology, ... (Nasdaq: EMIS ) has announced that Nicholas ... of Strategy and Development. In this,capacity, Mr. Hart ... aspects of the company,s Eligen(R) technology, including,Eligen(R) B12., ...
... & Co., Inc. Biomarker,Imaging Program -, - ... Broadens Applications in Key Areas of Disease Research ... VisEn Medical, Inc., a leader,in fluorescence in ... commercial launch of its IntegriSenseTM fluorescence in vivo,imaging ...
... Detect Toxicity -, HOPKINTON, Mass., Aug. 19 ... that it has received a $1.1,million task order under ... This task order was issued,pursuant to a contract that ... the ToxCast program. The contract provides for up to ...
Cached Biology Technology:Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development 2Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 2Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 3Caliper Life Sciences Receives $1.1 Million Task Order from the EPA's ToxCast(TM) Screening Program 4
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... Eos: Long-Term Ecological Research and Network-Level Science, , Imagine ... wide range of ecosystems was responding to global changes ... powerful if it coupled multiple decades of information about ... and models from dozens of different ecosystem types. ... Long-Term Ecological Research (LTER) Network, which will soon celebrate ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... of storm surge and sea-level rise have become ... weeks following Hurricane Sandy,s catastrophic landfall along the ... Brubaker of the Virginia Institute of Marine Science ... sea-level variabilitythe "intra-seasonal" changes that occupy the middle ...
... a glacier,s past, potentially allowing them to more accurately assess how ... been published today, 27 November, in IOP Publishing,s journal Environmental ... can be extended way past the instrumental record. Much ... is, measuring the width of rings on the stem of a ...
... 26, 2012 Webcast AdvisoryWhat:Announcement of a state-of-the-art pediatric ... team racing to unlock genomic codes and develop ... biomedical breakthroughs that will give new hope to ... Hospital, in collaboration with Translational Genomics Research Institute ...
Cached Biology News:Researcher studies 'middle ground' of sea-level change 2Researcher studies 'middle ground' of sea-level change 3Researcher studies 'middle ground' of sea-level change 4Researcher studies 'middle ground' of sea-level change 5Shrubs lend an insight into a glacier's past 2
...
... Clone/PAD: ZMD.358. Immunogen: Synthetic ... region of human mouse and ... with human and mouse LRP5 ... (positive controls: mouse LRP5-pSEC-tag-transfected 293T ...
...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: